IGM Biosciences (NASDAQ:IGMS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 3 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 2 | 1 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for IGM Biosciences, presenting an average target of $16.17, a high estimate of $21.00, and a low estimate of $12.00. Marking an increase of 131.0%, the current average surpasses the previous average price target of $7.00.
Decoding Analyst Ratings: A Detailed Look
A comprehensive examination...
Login or create a forever free account to read this news
Sign up/Log in